^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + Zejula (niraparib) (PARP inhibitor) + Jivadco (trastuzumab duocarmazine) (HER2-targeted antibody-drug conjugate, DNA replication inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4043: SYD985 synergy with PARP inhibitors (PARPi) in human tumor cell lines and patient-derived xenografts (PDXs)
Published date:
05/15/2020
Excerpt:
...niraparib and olaparib act in synergy with SYD985 in killing human HER2-expressing tumor cells in vitro, both in high HER2 (BT-474, AU-565, UACC-893) and low HER2 (NIH:OVCAR-3; TOV-112D) expressing cells.
DOI:
10.1158/1538-7445.AM2020-4043
